A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 4, 2012, Pages 819-831

  Maruri, Fernanda ^a   Sterling, Timothy R ^a   Kaiga, Anne W ^b   Blackman, Amondrea ^a   van der heijden, Yuri F ^a   Mayer, Claudine ^c,d,e   Cambau, Emmanuelle ^e,f,g   Aubry, Alexandra ^f,h,i  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c INSTITUT PASTEUR   (France)

^d CNRS   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f AP HP HÔpital Pitié Salpêtrière Centre National de Référence des Mycobactéries de la Résistance des Mycobactéries aux Antituberculeux Bacteriologie Hygiene   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

gyrA; gyrB; M. tuberculosis; QRDRs

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; CODON; DISEASE ASSOCIATION; GENE SEQUENCE; HUMAN; MEDLINE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SYSTEMATIC REVIEW; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84858665539     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr566     Document Type: Article

References (67)

1. American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52: 1-77.
2. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
3. Takiff HE, Salazar L, Guerrero C et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38: 773-80.
4. Mdluli K, Ma Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets 2007; 7: 159-68.
5. Hooper D, Rubinstein E. Quinolone Antimicrobial Agents. Washington, DC: ASM Press, 2008.
6. Cheng AF, Yew WW, Chan EW et al. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2004; 48: 596-601.
7. Lee AS, Tang LL, Lim IH et al. Characterization of pyrazinamide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore. Int J Infect Dis 2002; 6: 48-51.
8. Pitaksajjakul P, Wongwit W, Punprasit W et al. Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J Trop Med Public Health 2005; 36 Suppl 4: 228-37.
9. Huang TS, Kunin CM, Shin-Jung Lee S et al. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 2005; 56: 1058-62.
10. Siddiqi N, Shamim M, Hussain S et al. Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India. Antimicrob Agents Chemother 2002; 46: 443-50.
11. Soudani A, Hadjfredj S, Zribi M et al. First report of molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates from a Tunisian hospital. Clin Microbiol Infect 2010; 16: 1454-7.
12. Sullivan EA, Kreiswirth BN, Palumbo L et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995; 345: 1148-50.
13. Hegde SS, Vetting MW, Roderick SL et al. A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science 2005; 308: 1480-3.
14. Pasca MR, Guglierame P, Arcesi F et al. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004; 48: 3175-8.
15. Takiff HE, Cimino M, Musso MC et al. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc Natl Acad Sci USA 1996; 93: 362-6.
16. Feuerriegel S, Cox HS, Zarkua N et al. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob Agents Chemother 2009; 53: 3353-6.
17. Antonova OV, Gryadunov DA, Lapa SA et al. Detection of mutations in Mycobacterium tuberculosis genome determining resistance to fluoroquinolones by hybridization on biological microchips. Bull Exp Biol Med 2008; 145: 108-13.
18. Aubry A, Veziris N, Cambau E et al. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother 2006; 50: 104-12.
19. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47: 1767-72.
20. Kam KM, Yip CW, Cheung TL et al. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Resist 2006; 12: 7-11.
21. Mokrousov I, Otten T, Manicheva O et al. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob Agents Chemother 2008; 52: 2937-9.
22. Perdigao J, Macedo R, Malaquias A et al. Genetic analysis of extensively drug-resistant Mycobacterium tuberculosis strains in Lisbon, Portugal. J Antimicrob Chemother 2010; 65: 224-7.
23. Sekiguchi J, Miyoshi-Akiyama T, Augustynowicz-Kopec E et al. Detection of multidrug resistance in Mycobacterium tuberculosis. J Clin Microbiol 2007; 45: 179-92.
24. Sulochana S, Narayanan S, Paramasivan CN et al. Analysis of fluoroquinolone resistance in clinical isolates of Mycobacterium tuberculosis from India. J Chemother 2007; 19: 166-71.
25. Umubyeyi AN, Rigouts L, Shamputa IC et al. Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey. J Antimicrob Chemother 2007; 59: 1031-3.
26. Von Groll A, Martin A, Jureen P et al. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 2009; 53: 4498-500.
27. Williams KJ, Chan R, Piddock LJ. gyrA of ofloxacin-resistant clinical isolates of Mycobacterium tuberculosis from Hong Kong. J Antimicrob Chemother 1996; 37: 1032-4.
28. Chang KC, Yew WW, Chan RC. Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2010; 65: 1551-61.
29. Kim SJ, Espinal MA, Abe C et al. Is second-line anti-tuberculosis drug susceptibility testing reliable? Int J Tuberc Lung Dis 2004; 8: 1157-8.
30. WHO. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. Geneva: WHO, 2010. http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf (13 June 2011, date last accessed).
31. Giannoni F, Iona E, Sementilli F et al. Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 2928-33.
32. Kiet VS, Lan NT, An DD et al. Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis. J Clin Microbiol 2010; 48: 2934-9.
33. Brossier F, Veziris N, Aubry A et al. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010; 48: 1683-9.
34. Camus JC, Pryor MJ, Medigue C et al. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 2002; 148: 2967-73.
35. Sandgren A, Strong M, Muthukrishnan P et al. Tuberculosis drug resistance mutation database. PLoS Med 2009; 6: e2.
36. Kocagoz T, Hackbarth CJ, Unsal I et al. Gyrase mutations in laboratoryselected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1996; 40: 1768-74.
37. Lau RW, Ho PL, Kao RY et al. Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74. Antimicrob Agents Chemother 2010; 55: 608-14.
38. Alangaden GJ, Manavathu EK, Vakulenko SB et al. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother 1995; 39: 1700-3.
39. Cambau E, Sougakoff W, Besson M et al. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 1994; 170: 479-83.
40. Mitarai S. Mycobacterium tuberculosis and gyrA variation in Zambia. Trop Med Health 2005; 33: 91-4.
41. Sougakoff W, Lemaitre N, Cambau E et al. Nonradioactive single-strand conformation polymorphism analysis for detection of fluoroquinolone resistance in mycobacteria. Eur J Clin Microbiol Infect Dis 1997; 16: 395-8.
42. Duong DA, Nguyen TH, Nguyen TN et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. Antimicrob Agents Chemother 2009; 53: 4835-9.
43. Yin X, Yu Z. Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China. J Infect 2010; 61: 150-4.
44. Zhou J, Dong Y, Zhao X et al. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis 2000; 182: 517-25.
45. Veziris N, Martin C, Brossier F et al. Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance. Eur J Clin Microbiol Infect Dis 2007; 26: 423-5.
46. Shi R, Zhang J, Li C et al. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J Clin Microbiol 2006; 44: 4566-8.
47. Sun Z, Zhang J, Zhang X et al. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int J Antimicrob Agents 2008; 31: 115-21.
48. van Doorn HR, An DD, de Jong MD et al. Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR. Int J Tuberc Lung Dis 2008; 12: 736-42.
49. Rinder H, Mieskes KT, Loscher T. Heteroresistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2001; 5: 339-45.
50. Hofmann-Thiel S, van Ingen J, Feldmann K et al. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur Respir J 2009; 33: 368-74.
51. Lau RW, Ho PL, Kao RY et al. Rapid diagnosis of multidrug-resistant smear-positive pulmonary tuberculosis. Int J Antimicrob Agents 2010; 35: 202-3.
52. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1320-30.
53. Evans J, Segal H. Novel multiplex allele-specific PCR assays for the detection of resistance to second-line drugs in Mycobacterium tuberculosis. J Antimicrob Chemother 2010; 65: 897-900.
54. Chan RC, Hui M, Chan EW et al. Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J Antimicrob Chemother 2007; 59: 866-73.
55. Bravo LT, Tuohy MJ, Ang C et al. Pyrosequencing for rapid detection of Mycobacterium tuberculosis resistance to rifampin, isoniazid, and fluoroquinolones. J Clin Microbiol 2009; 47: 3985-90.
56. Post FA, Willcox PA, Mathema B et al. Genetic polymorphism in Mycobacterium tuberculosis isolates from patients with chronic multidrug-resistant tuberculosis. J Infect Dis 2004; 190: 99-106.
57. WHO. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. Geneva: WHO, 2008. http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=&codlan=&codcol=15&codcch=2663 (13 June 2011, date last accessed).
58. Poissy J, Aubry A, Fernandez C et al. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 2010; 54: 4765-71.
59. Feasey NA, Pond M, Coleman D et al. Moxifloxacin and pyrazinamide susceptibility testing in a complex case of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2011; 15: 417-20.
60. Perlman DC, El Sadr WM, Heifets LB et al. Susceptibility to levofloxacin of Mycobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinical Trials Group222 Protocol Team. AIDS1997;11: 1473-8.
61. Bozeman L, Burman W, Metchock B et al. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 2005; 40: 386-91.
62. Sun Z, Chao Y, Zhang X et al. Characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates in China. J Clin Microbiol 2008; 46: 4075-7.
63. Xu C, Kreiswirth BN, Sreevatsan S et al. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrugresistant Mycobacterium tuberculosis. J Infect Dis 1996; 174: 1127-30.
64. Matrat S, Veziris N, Mayer C et al. Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones. Antimicrob Agents Chemother 2006; 50: 4170-3.
65. Siddiqi N, Shamim M, Jain NK et al. Molecular genetic analysis of multi-drug resistance in Indian isolates of Mycobacterium tuberculosis. Mem Inst Oswaldo Cruz 1998; 93: 589-94.
66. Wang JY, Lee LN, Lai HC et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007; 59: 860-5.
67. Pantel A, Brossier F, Bastian S. Mutations in the GyrB subunit of clinical Mycobacterium tuberculosis strains: consequences on resistance to fluoroquinolones. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract C1-085. American Society for Microbiology, Washington, DC, USA.